443 related articles for article (PubMed ID: 18685487)
1. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
2. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
Sharma SG; Gokden M; McKenney JK; Phan DC; Cox RM; Kelly T; Gokden N
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):494-8. PubMed ID: 21102195
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin.
Mentrikoski MJ; Wendroth SM; Wick MR
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):635-41. PubMed ID: 25279712
[TBL] [Abstract][Full Text] [Related]
4. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology.
Gokden N; Kemp SA; Gokden M
Diagn Cytopathol; 2008 Jul; 36(7):473-7. PubMed ID: 18528893
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.
Sangoi AR; Fujiwara M; West RB; Montgomery KD; Bonventre JV; Higgins JP; Rouse RV; Gokden N; McKenney JK
Am J Surg Pathol; 2011 May; 35(5):678-86. PubMed ID: 21490444
[TBL] [Abstract][Full Text] [Related]
6. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma.
Lin F; Zhang PL; Yang XJ; Shi J; Blasick T; Han WK; Wang HL; Shen SS; Teh BT; Bonventre JV
Am J Surg Pathol; 2007 Mar; 31(3):371-81. PubMed ID: 17325478
[TBL] [Abstract][Full Text] [Related]
7. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai Q; Javed R; Shen SS; Coffey D; Krishnan B; Truong LD
Arch Pathol Lab Med; 2010 Aug; 134(8):1121-9. PubMed ID: 20670131
[TBL] [Abstract][Full Text] [Related]
8. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10.
Sangoi AR; Karamchandani J; Kim J; Pai RK; McKenney JK
Adv Anat Pathol; 2010 Nov; 17(6):377-93. PubMed ID: 20966644
[TBL] [Abstract][Full Text] [Related]
9. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications.
Bakshi N; Kunju LP; Giordano T; Shah RB
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):310-5. PubMed ID: 17721277
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Gupta R; Balzer B; Picken M; Osunkoya AO; Shet T; Alsabeh R; Luthringer D; Paner GP; Amin MB
Am J Surg Pathol; 2009 Feb; 33(2):241-7. PubMed ID: 18941400
[TBL] [Abstract][Full Text] [Related]
11. GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics.
Mantilla JG; Antic T; Tretiakova M
Hum Pathol; 2017 Aug; 66():152-158. PubMed ID: 28705707
[TBL] [Abstract][Full Text] [Related]
12. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
13. Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study.
Huang W; Kanehira K; Drew S; Pier T
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):12-7. PubMed ID: 18769342
[TBL] [Abstract][Full Text] [Related]
14. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'Renal Cell Carcinoma Marker'.
McGregor DK; Khurana KK; Cao C; Tsao CC; Ayala G; Krishnan B; Ro JY; Lechago J; Truong LD
Am J Surg Pathol; 2001 Dec; 25(12):1485-92. PubMed ID: 11717537
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration.
Wasco MJ; Pu RT
Diagn Cytopathol; 2008 Aug; 36(8):568-73. PubMed ID: 18618717
[TBL] [Abstract][Full Text] [Related]
16. Pax-2 expression in adult renal tumors.
Daniel L; Lechevallier E; Giorgi R; Sichez H; Zattara-Cannoni H; Figarella-Branger D; Coulange C
Hum Pathol; 2001 Mar; 32(3):282-7. PubMed ID: 11274636
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of renal cell carcinoma marker in cytopathology.
Gokden N; Mukunyadzi P; James JD; Gokden M
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):116-9. PubMed ID: 12777993
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
Pan CC; Chen PC; Ho DM
Histopathology; 2004 Nov; 45(5):452-9. PubMed ID: 15500648
[TBL] [Abstract][Full Text] [Related]
19. Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy.
Simsir A; Chhieng D; Wei XJ; Yee H; Waisman J; Cangiarella J
Diagn Cytopathol; 2005 Jul; 33(1):3-7. PubMed ID: 15945081
[TBL] [Abstract][Full Text] [Related]
20. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
